1. Home
  2. MESO
  3. MESO News

Latest Mesoblast Limited (MESO) News on July 26, 2024

FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
MESO

Pharmaceutical Technology

3 days ago

FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy

MESO

MT Newswires

3 days ago

Mesoblast Says FDA Accepted Resubmitted Biologics License Application for Ryoncil; Shares Rise Pre-Bell

FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
MESO

GlobeNewswire

3 days ago

FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast begins subject enrolment in Phase III back pain treatment trial
MESO

Clinical Trials Arena

5 days ago

Mesoblast begins subject enrolment in Phase III back pain treatment trial

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
MESO

GlobeNewswire

5 days ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects
MESO

Simply Wall St.

16 days ago

July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects

Insider-Owned ASX Growth Companies To Watch In July 2024
MESO

Simply Wall St.

16 days ago

Insider-Owned ASX Growth Companies To Watch In July 2024

MESO

MT Newswires

18 days ago

Mesoblast Resubmits Ryoncil Biologics License Application

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
MESO

GlobeNewswire

18 days ago

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
MESO

Zacks

24 days ago

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
MESO

GlobeNewswire

a month ago

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

ASX Growth Companies With High Insider Ownership To Watch In June 2024
MESO

Simply Wall St.

a month ago

ASX Growth Companies With High Insider Ownership To Watch In June 2024

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120%
MESO

Simply Wall St.

a month ago

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120%

High Insider Ownership Growth Stocks On The ASX In June 2024
MESO

Simply Wall St.

a month ago

High Insider Ownership Growth Stocks On The ASX In June 2024

Exploring Three ASX Growth Companies With Significant Insider Ownership
MESO

Simply Wall St.

a month ago

Exploring Three ASX Growth Companies With Significant Insider Ownership

Mesoblast Corporate Presentation at Investor Conference
MESO

GlobeNewswire

2 months ago

Mesoblast Corporate Presentation at Investor Conference

ASX Growth Companies With High Insider Ownership And At Least 26% Earnings Growth
MESO

Simply Wall St.

2 months ago

ASX Growth Companies With High Insider Ownership And At Least 26% Earnings Growth

ASX Growth Leaders With High Insider Ownership Explored
MESO

Simply Wall St.

2 months ago

ASX Growth Leaders With High Insider Ownership Explored

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Of At Least 14%
MESO

Simply Wall St.

2 months ago

Three ASX Growth Companies With High Insider Ownership And Earnings Growth Of At Least 14%

May 2024 Insight Into ASX Growth Companies With High Insider Ownership
MESO

Simply Wall St.

2 months ago

May 2024 Insight Into ASX Growth Companies With High Insider Ownership

ASX Growth Companies With High Insider Ownership And At Least 14% Earnings Growth
MESO

Simply Wall St.

2 months ago

ASX Growth Companies With High Insider Ownership And At Least 14% Earnings Growth

Exploring Three ASX Growth Companies With High Insider Ownership
MESO

Simply Wall St.

2 months ago

Exploring Three ASX Growth Companies With High Insider Ownership

Exploring Three ASX Growth Companies With Significant Insider Ownership
MESO

Simply Wall St.

2 months ago

Exploring Three ASX Growth Companies With Significant Insider Ownership

ASX Growth Companies With High Insider Ownership And Revenue Increases Up To 76%
MESO

Simply Wall St.

2 months ago

ASX Growth Companies With High Insider Ownership And Revenue Increases Up To 76%

ASX Growth Leaders With High Insider Ownership To Watch
MESO

Simply Wall St.

2 months ago

ASX Growth Leaders With High Insider Ownership To Watch

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
MESO

GlobeNewswire

3 months ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%
MESO

Simply Wall St.

3 months ago

Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
MESO

Zacks

4 months ago

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant
MESO

Benzinga

4 months ago

After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
MESO

GlobeNewswire

4 months ago

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
MESO

GlobeNewswire

4 months ago

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
MESO

GlobeNewswire

5 months ago

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript
MESO

Insider Monkey

5 months ago

Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript

Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
MESO

Simply Wall St.

5 months ago

Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
MESO

GlobeNewswire

5 months ago

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Mesoblast Financial Results and Corporate Update Webcast
MESO

GlobeNewswire

5 months ago

Mesoblast Financial Results and Corporate Update Webcast

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
MESO

GlobeNewswire

5 months ago

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
MESO

GlobeNewswire

6 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report
MESO

ACCESSWIRE

6 months ago

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report

Bartesian Leverages Strategic Partnership with iHeartMedia to Drive Expansion in 2024
MESO

PR Newswire

6 months ago

Bartesian Leverages Strategic Partnership with iHeartMedia to Drive Expansion in 2024

Mid Penn Bancorp Full Year 2023 Earnings: EPS Misses Expectations
MESO

Simply Wall St.

6 months ago

Mid Penn Bancorp Full Year 2023 Earnings: EPS Misses Expectations

OneWater Marine (ONEW) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
MESO

Zacks

6 months ago

OneWater Marine (ONEW) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

MESO

Associated Press Finance

6 months ago

CNB: Q4 Earnings Snapshot

CNB Financial Corporation Reports Fourth Quarter and Full-Year 2023 Results
MESO

GlobeNewswire

6 months ago

CNB Financial Corporation Reports Fourth Quarter and Full-Year 2023 Results

Maxeon Solar Technologies Recognized as One of the World's Top 50 Most Sustainable Corporations
MESO

PR Newswire

6 months ago

Maxeon Solar Technologies Recognized as One of the World's Top 50 Most Sustainable Corporations

Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
MESO

Zacks

6 months ago

Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
MESO

GlobeNewswire

6 months ago

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

With 50% ownership of the shares, Quipt Home Medical Corp. (TSE:QIPT) is heavily dominated by institutional owners
MESO

Simply Wall St.

6 months ago

With 50% ownership of the shares, Quipt Home Medical Corp. (TSE:QIPT) is heavily dominated by institutional owners

KNOT Offshore Partners LP Announces Fourth Quarter 2023 Cash Distribution
MESO

Business Wire

6 months ago

KNOT Offshore Partners LP Announces Fourth Quarter 2023 Cash Distribution

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
MESO

GlobeNewswire

6 months ago

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

MESO

Market Exclusive

6 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Shareholders in Organogenesis Holdings (NASDAQ:ORGO) are in the red if they invested five years ago
MESO

Simply Wall St.

6 months ago

Shareholders in Organogenesis Holdings (NASDAQ:ORGO) are in the red if they invested five years ago

Canopy Growth Announces US$30 Million Private Placement
MESO

CNW Group

7 months ago

Canopy Growth Announces US$30 Million Private Placement

Mesoblast (ASX:MSB) investors are sitting on a loss of 88% if they invested three years ago
MESO

Simply Wall St.

7 months ago

Mesoblast (ASX:MSB) investors are sitting on a loss of 88% if they invested three years ago

Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MESO

Zacks

7 months ago

Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Is KNOT Offshore Partners (KNOP) Stock Undervalued Right Now?
MESO

Zacks

7 months ago

Is KNOT Offshore Partners (KNOP) Stock Undervalued Right Now?

MESO

GlobeNewswire

7 months ago

Quipt Home Medical Corp. Announces Filing of Preliminary Base Shelf Prospectus to Replace Recently Expired Base Shelf Prospectus

At US$8.09, Is Pangaea Logistics Solutions, Ltd. (NASDAQ:PANL) Worth Looking At Closely?
MESO

Simply Wall St.

7 months ago

At US$8.09, Is Pangaea Logistics Solutions, Ltd. (NASDAQ:PANL) Worth Looking At Closely?

3 Mortgage REITs With Yields Up To 21.04%
MESO

Benzinga

7 months ago

3 Mortgage REITs With Yields Up To 21.04%

New Strong Buy Stocks for December 22nd
MESO

Zacks

7 months ago

New Strong Buy Stocks for December 22nd

3 Mortgage & Related Services Stocks to Watch Amid Ongoing Woes
MESO

Zacks

7 months ago

3 Mortgage & Related Services Stocks to Watch Amid Ongoing Woes

5 Stocks to Ride the Santa Claus Rally
MESO

Zacks

7 months ago

5 Stocks to Ride the Santa Claus Rally

ibex Welcomes Jason Lockbaum as Senior Vice President, Healthcare Sales
MESO

GlobeNewswire

7 months ago

ibex Welcomes Jason Lockbaum as Senior Vice President, Healthcare Sales

MESO

GlobeNewswire

7 months ago

Quipt Home Medical Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results Posting Revenue Growth of 59% and Adjusted EBITDA Growth of 73%

The 3 Best Performing Stocks of 2023
MESO

InvestorPlace

7 months ago

The 3 Best Performing Stocks of 2023

This Children's Place Insider Increased Their Holding By 13% Last Year
MESO

Simply Wall St.

7 months ago

This Children's Place Insider Increased Their Holding By 13% Last Year

Why Fast-paced Mover Ocwen (OCN) Is a Great Choice for Value Investors
MESO

Zacks

7 months ago

Why Fast-paced Mover Ocwen (OCN) Is a Great Choice for Value Investors

DouYu International Holdings Limited (NASDAQ:DOYU) Q3 2023 Earnings Call Transcript
MESO

Insider Monkey

8 months ago

DouYu International Holdings Limited (NASDAQ:DOYU) Q3 2023 Earnings Call Transcript

Wall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should Know
MESO

Zacks

8 months ago

Wall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should Know

MESO

Reuters

8 months ago

UPDATE 1-Replimune's skin cancer drug fails in mid-stage study

MESO

GlobeNewswire

8 months ago

Quipt Home Medical Corp. to Announce Fourth Quarter and Full Year 2023 Financial Results on December 18, 2023

MESO

Reuters

8 months ago

CORRECTED-Replimune's skin cancer drug fails in mid-stage study

MESO

GlobeNewswire

8 months ago

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

L.B. Foster to Present at Sidoti and Singular Conferences; Updated Corporate Investor Presentation to be Posted Online
MESO

GlobeNewswire

8 months ago

L.B. Foster to Present at Sidoti and Singular Conferences; Updated Corporate Investor Presentation to be Posted Online

Postal Realty to Participate in Jefferies Real Estate Conference
MESO

GlobeNewswire

8 months ago

Postal Realty to Participate in Jefferies Real Estate Conference

Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
MESO

GlobeNewswire

8 months ago

Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release

Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
MESO

Business Wire

8 months ago

Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
MESO

GlobeNewswire

8 months ago

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Investors in HomeTrust Bancshares (NASDAQ:HTBI) have seen returns of 27% over the past three years
MESO

Simply Wall St.

8 months ago

Investors in HomeTrust Bancshares (NASDAQ:HTBI) have seen returns of 27% over the past three years

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
MESO

Zacks

8 months ago

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

A Look At The Intrinsic Value Of Quipt Home Medical Corp. (TSE:QIPT)
MESO

Simply Wall St.

8 months ago

A Look At The Intrinsic Value Of Quipt Home Medical Corp. (TSE:QIPT)

Virtus Total Return Fund Inc. Announces Distributions and Discloses Sources of Distribution – Section 19(a) Notice
MESO

Business Wire

8 months ago

Virtus Total Return Fund Inc. Announces Distributions and Discloses Sources of Distribution – Section 19(a) Notice

Certain Virtus Closed-End Funds Announce Three Monthly Distributions: NCV, NCZ, CBH
MESO

Business Wire

8 months ago

Certain Virtus Closed-End Funds Announce Three Monthly Distributions: NCV, NCZ, CBH

Executive Chairman of Lyra Therapeutics Harlan Waksal Buys 11% More Shares
MESO

Simply Wall St.

8 months ago

Executive Chairman of Lyra Therapeutics Harlan Waksal Buys 11% More Shares

L.B. Foster (FSTR) Q3 Earnings Miss Estimates, Revenues Beat
MESO

Zacks

8 months ago

L.B. Foster (FSTR) Q3 Earnings Miss Estimates, Revenues Beat

Entravision Appoints Jack Randall as Executive Vice President of Political and Strategic Sales
MESO

Business Wire

8 months ago

Entravision Appoints Jack Randall as Executive Vice President of Political and Strategic Sales

Carter Bankshares, Inc.'s (NASDAQ:CARE) top owners are retail investors with 55% stake, while 41% is held by institutions
MESO

Simply Wall St.

8 months ago

Carter Bankshares, Inc.'s (NASDAQ:CARE) top owners are retail investors with 55% stake, while 41% is held by institutions

Telos Corporation (NASDAQ:TLS) Q3 2023 Earnings Call Transcript
MESO

Insider Monkey

9 months ago

Telos Corporation (NASDAQ:TLS) Q3 2023 Earnings Call Transcript

MESO

Thomson Reuters StreetEvents

9 months ago

Q3 2023 Telos Corp Earnings Call

Adams Diversified Equity Fund Declares Year-End Distribution; Exceeds Its Annual 6% Minimum Distribution Rate Commitment
MESO

GlobeNewswire

9 months ago

Adams Diversified Equity Fund Declares Year-End Distribution; Exceeds Its Annual 6% Minimum Distribution Rate Commitment

Adams Natural Resources Fund Declares Year-End Distribution; Exceeds Its Annual 6% Minimum Distribution Rate Commitment
MESO

GlobeNewswire

9 months ago

Adams Natural Resources Fund Declares Year-End Distribution; Exceeds Its Annual 6% Minimum Distribution Rate Commitment

MESO

PR Newswire

9 months ago

New England Realty Associates LP Announces Fourth-Quarter Distribution on Class A Units and Depositary Receipts

Telos Corp (TLS) Exceeds Q3 Guidance with Expanded Gross Margin and Positive Cash Flow
MESO

GuruFocus.com

9 months ago

Telos Corp (TLS) Exceeds Q3 Guidance with Expanded Gross Margin and Positive Cash Flow

L.B. Foster Company (NASDAQ:FSTR) Q3 2023 Earnings Call Transcript
MESO

Insider Monkey

9 months ago

L.B. Foster Company (NASDAQ:FSTR) Q3 2023 Earnings Call Transcript

MESO

GlobeNewswire

9 months ago

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

MESO

PR Newswire

9 months ago

ATRenew to Report Third Quarter 2023 Financial Results on November 22, 2023

MESO

PR Newswire

9 months ago

ATRenew Recognized by the Reuters Responsible Business Awards 2023

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
MESO

GlobeNewswire

9 months ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Share on Social Networks: